

United States Patent and Trademark Office

CNITED STATES DEPARTMENT OF COMMERCE Gnited States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/908,943	07/19/2001		Rigiang Yan	29915/00281A.US	1034	
4743	7590	05/03/2005		EXA	EXAMINER	
MARSHAI	LL, GERS	STEIN & BORUN	CELSA, E	CELSA, BENNETT M		
233 S. WAC	KER DRI	VE, SUITE 6300				
SEARS TO	WER		•	ART UNIT	PAPER NUMBER	
CHICAGO II 60606				1620		

DATE MAILED: 05/03/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	09/908,943	YAN ET AL.	
Office Action Summary	Examiner	Art Unit	
·	Bennett Celsa	1639	
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet	with the correspondence a	ddress
A SHORTENED STATUTORY PERIOD FOR REF THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a r - If NO period for reply is specified above, the maximum statutory erior. - Failure to reply within the set or extended period for reply will, by stat Any reply received by the Office later than three months after the ma earned patent term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may reply within the statutory minimum of the statutory minim	a reply be timely filed nirty (30) days will be considered tim DNTHS from the mailing date of this ABANDONED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on 31 2a) This action is FINAL. 2b) This action is FINAL. 3) Since this application is in condition for allow closed in accordance with the practice unde	his action is non-final. vance except for formal ma	*	ne merits is
Disposition of Claims			
4) Claim(s) 102-131 is/are pending in the appli 4a) Of the above claim(s) is/are withd 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 102-131 are subject to restriction a	rawn from consideration.		,
Application Papers			
9) The specification is objected to by the Exami 10) The drawing(s) filed on is/are: a) a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct and the	ccepted or b) objected to the drawing(s) be held in abey ection is required if the drawir	ance. See 37 CFR 1.85(a). ng(s) is objected to. See 37 C	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure * See the attached detailed Office action for a li	ents have been received. ents have been received in riority documents have bee eau (PCT Rule 17.2(a)).	Application No In received in this Nationa	l Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/C Paper No(s)/Mail Date	Paper No. (5) Notice of 6) Other:		
PTOL-326 (Rev. 1-04) Office	Action Summary	Part of Paper No./Mail I	Jate 20050421

Application/Control Number: 09/908,943

Art Unit: 1639

DETAILED ACTION: Further Restriction/Election

Status of the Claims

Claims 102-131 are currently pending.

Applicant's election of Groups 5430-8370 (methods for assaying beta-secretase modulators) and SYEV as the peptide substrate motif in the correspondence dated 1/31/05 is acknowledged.

In light of applicant's newly presented claims and upon further consideration, the following Restriction/election of species is being instituted.

NOTE: this application has been transferred to PRIMARY EXAMINER CELSA:

AU 1639 (see correspondence information below).

Election/Restrictions (Lack of Unity)

This application contains claims directed to the following patentably distinct species of the claimed invention:

ASSAY MILEU (lack of unity/burdensome search):

I. In vitro assay: Claims 102-128 and 131, drawn to an *in vitro* competitive binding assay for a modulator of beta secretase activity, classified in class 435, subclass 7.1.

OR

II. In vivo assay :Claims 129 and 130, drawn to an *in vivo* (e.g. transgenic non-human mammal) competitive binding assay, classified in class 424, subclass 93.1.

Art Unit: 1639

The above-cited methods of Groups I and II lack unity of invention since these inventions fail to share a "special" common technical feature since:

A polypeptide with beta secretase APP processing activity (e.g. Hu-Asp2) and a substrate (seq. 113: EVNL-DAEFR) for use in an assay are known in the art (e.g. see Specification pages 1-2) as are secretase substrates (VKM-DAEF) comprising a P2P1-P1'P2' motif comprising KMDA which is within the scope of the presently claimed invention. See Tsien et al. US Pat. No. 5,981,200 (11/99) at col. 14 (Table III) and patent claims 1-7, especially claims 1, 9, 12 etc. Additionally, the methods require different and separately burdensome manual/computer bibliographic and classification in patent and literature database due to their divergent subject matter.

Accordingly, applicant must elect either Group I. Or Group II above.

POLYPEPTIDE WITH BETA SECRETASE APP ACTIVITY (lack of unity/burdensome search):

The claimed invention encompasses beta secretase polypeptides (E.g. SEQ 2 OR 4 etc.) comprising different amino acid sequences which although sharing a common utility, nevertheless fail to share a substantial structural feature disclosed as being essential to that utility and thus lack unity of invention. See MPEP 803.02. Additionally, the bibliographic and sequence searches for the scope of secretase polypeptides (and corresponding nucleic acids) would be unduly burdensome.

Application/Control Number: 09/908,943

Art Unit: 1639

Accordingly, applicant must elect a single secretase polypeptide sequence and if available a corresponding coding nucleic acid sequence and indicate claims readable thereon.

SECRETASE SUBSTRATE (species election: burdensome search):

The claim (elected) invention comprises the use of substrate peptide motifs which comprise the tetrapeptide SYEV in the presently claimed assays. However, the scope of peptides that comprise this core structure is huge since there is no limit placed on the number of amino acids and the composition of amino acids N- or C- terminal to this motif. Accordingly, the bibliographic, classification and sequence searches for the entire scope of SYEV containing peptides would be unduly burdensome.

Accordingly, applicant must elect a single peptide species (e.g. a single compound) which comprises SYEV and indicate claims readable thereon.

Applicant is advised that a reply to this requirement must include an identification of the species (e.g. mileu, secretase peptide and substrate) that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record

Art Unit: 1639

showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Future Correspondences:

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bennett Celsa whose telephone number is 571-272-0807. The examiner can normally be reached on 8-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on 571-272-0811. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Bennett Celsa Primary Examiner Art Unit 1639

BC April 21, 2005